Pharmacologic characterization of acute @entity8685 @entity734 in the XXXX .

@entity1 @entity149 @entity1245 @entity5828 @entity8685 @entity5757 @entity35 @entity17996 @entity734
A single intoxicating dose of @entity8685 @entity5828 (p.o.) in the @entity35 can induce quantifiable manifestations of @entity734 . @entity734 was revealed by antagonist precipitation ( @entity5757 , @entity17996 ) as well as spontaneous emergence of neurobehavioral signs of withdrawal observed by multiple raters blind to treatments. @entity5757 was 45% more effective than @entity17996 in both reversing @entity8685 intoxication and expressing withdrawal signs. The severity of @entity5757 -precipitated withdrawal varied with @entity8685 dose, @entity5757 dose and the agonist-antagonist dose interval. Maximal precipitated @entity734 was evoked 3 days after @entity8685 @entity5828 (450 mg/kg) by @entity5757 (25 mg/kg i.p.). The precipitated syndrome consisted of tail erection, reduced motor activity, high step, curled claw, arched back, muscle hypertonus and piloerection. @entity5757 -precipitated @entity734 emerged between 28 and 52 hr, peaked at 76 hr and disappeared by 124 hr. Spontaneous withdrawal had emerged from 100 to 124 hr and then faded gradually. The neurobehavioral expression of @entity149 and its reversal were necessary but not sufficient conditions for the induction and expression of acute @entity8685 @entity734 . These results suggest caution in reviving acute @entity1245 -overdosed @entity1 to avoid iatrogenic withdrawal analogous to naloxone for opiates.
